ELDEPRYL
LOE Approachingselegiline hydrochloride
NDAORALCAPSULE
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Mechanism of Action
CLINICAL PHARMACOLOGY The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of Parkinson's disease are not fully understood. Inhibition of monoamine oxidase, type B, activity is generally considered to be of primary importance; in addition, there is evidence that…